Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how New Developments in Pharmacological Treatment of Obesity and Type 2 DiabetesBeyond and within GLP 1 Receptor Agonists When should I consider adding cagrilintide? Cagrilintide is the newest of the weight loss peptides. It works on amylin, which is found in the pancreas. Now, this can be a stand alone product but the Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Tirzepatide Dosage Chart: Where the Dose Sits in the FDA Schedule a PlexusDx